BACKGROUND: Uveal melanoma (UM) is the most common intraocular tumour in adults with a poor prognosis and extremely high mortality rate due to the development of metastatic disease. However, despite relatively good knowledge about the histological and genetic risk factors for metastasis development, there is no specific biomarker that would allow early detection of UM progression. Recently, exosomes and their molecular cargo have been widely studied in the search for potential biomarkers in several cancers. The purpose of this study was to analyze the inflammation-related protein cargo of exosomes derived from the serum of primary and metastatic UM patients and healthy donors. METHODS: The exosomes were isolated from the serum of primary and metastatic UM patients and healthy donors. Using multiplex immunoassay technology, we analyzed the concentration of 37 inflammation-related proteins in obtained exosomes. RESULTS: The analysis of protein cargo showed several molecules related to inflammation, such as interferon-gamma, interleukin 2, 22 and 12(p40), Pentraxin-3, TNFSF13B and TNFSF8 which were significantly enriched in metastatic UM exosomes. We showed a significant correlation between the disease stage and the concentration of these inflammation-related proteins from exosomal cargo. CONCLUSIONS: Based on the obtained results, we propose the panel of exosomal proteins for early detection of uveal melanoma progression into metastatic disease.

Department of Cell Biology Faculty of Science Charles University BIOCEV 25150 Vestec Czech Republic

Department of Chemotherapy Greater Poland Cancer Centre 61 866 Poznan Poland

Department of Electroradiology Poznan University of Medical Sciences 61 866 Poznan Poland

Department of Medical and Experimental Oncology Heliodor Swiecicki University Hospital Poznan University of Medical Sciences 61 866 Poznan Poland

Department of Oncologic Pathology and Prophylaxis Poznan University of Medical Sciences 61 866 Poznan Poland

Department of Orthopedics and Traumatology Poznan University of Medical Sciences 61 544 Poznan Poland

Department of Tumor Pathology Greater Poland Cancer Centre 61 866 Poznan Poland

Radiobiology Lab Department of Medical Physics Greater Poland Cancer 61 866 Poznan Poland

See more in PubMed

Berus T., Halon A., Markiewicz A., Orlowska-Heitzman J., Romanowska-Dixon B., Donizy P. Clinical, Histopathological and Cytogenetic Prognosticators in Uveal Melanoma—A Comprehensive Review. Anticancer Res. 2017;37:6541–6549. doi: 10.21873/anticanres.12110. PubMed DOI

Jager M.J., Shields C.L., Cebulla C.M., Abdel-Rahman M.H., Grossniklaus H.E., Stern M.H., Carvajal R.D., Belfort R.N., Jia R., Shields J.A., et al. Uveal melanoma. Nat. Rev. Dis. Primers. 2020;6:24. doi: 10.1038/s41572-020-0158-0. PubMed DOI

Robertson A.G., Shih J., Yau C., Gibb E.A., Oba J., Mungall K.L., Hess J.M., Uzunangelov V., Walter V., Danilova L., et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2017;32:204–220.e215. doi: 10.1016/j.ccell.2017.07.003. PubMed DOI PMC

Krantz B.A., Dave N., Komatsubara K.M., Marr B.P., Carvajal R.D. Uveal melanoma: Epidemiology, etiology, and treatment of primary disease. Clin. Ophthalmol. 2017;11:279–289. doi: 10.2147/OPTH.S89591. PubMed DOI PMC

Ortega M.A., Fraile-Martínez O., García-Honduvilla N., Coca S., Álvarez-Mon M., Buján J., Teus M.A. Update on uveal melanoma: Translational research from biology to clinical practice (Review) Int. J. Oncol. 2020;57:1262–1279. doi: 10.3892/ijo.2020.5140. PubMed DOI PMC

Damato B. Ocular treatment of choroidal melanoma in relation to the prevention of metastatic death—A personal view. Prog. Retin. Eye Res. 2018;66:187–199. doi: 10.1016/j.preteyeres.2018.03.004. PubMed DOI

Kaliki S., Shields C.L. Uveal melanoma: Relatively rare but deadly cancer. Eye. 2017;31:241–257. doi: 10.1038/eye.2016.275. PubMed DOI PMC

Terai M., Mu Z., Eschelman D.J., Gonsalves C.F., Kageyama K., Chervoneva I., Orloff M., Weight R., Mastrangelo M.J., Cristofanilli M., et al. Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells. EBioMedicine. 2015;2:1821–1826. doi: 10.1016/j.ebiom.2015.09.019. PubMed DOI PMC

Schuster R., Bechrakis N.E., Stroux A., Busse A., Schmittel A., Thiel E., Foerster M.H., Keilholz U. Prognostic relevance of circulating tumor cells in metastatic uveal melanoma. Oncology. 2011;80:57–62. doi: 10.1159/000328283. PubMed DOI

Tura A., Merz H., Reinsberg M., Lüke M., Jager M.J., Grisanti S., Lüke J. Analysis of monosomy-3 in immunomagnetically isolated circulating melanoma cells in uveal melanoma patients. Pigment. Cell Melanoma Res. 2016;29:583–589. doi: 10.1111/pcmr.12507. PubMed DOI

Bidard F.C., Madic J., Mariani P., Piperno-Neumann S., Rampanou A., Servois V., Cassoux N., Desjardins L., Milder M., Vaucher I., et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int. J. Cancer. 2014;134:1207–1213. doi: 10.1002/ijc.28436. PubMed DOI

Achberger S., Aldrich W., Tubbs R., Crabb J.W., Singh A.D., Triozzi P.L. Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. Mol. Immunol. 2014;58:182–186. doi: 10.1016/j.molimm.2013.11.018. PubMed DOI PMC

Russo A., Caltabiano R., Longo A., Avitabile T., Franco L.M., Bonfiglio V., Puzzo L., Reibaldi M. Increased Levels of miRNA-146a in Serum and Histologic Samples of Patients with Uveal Melanoma. Front Pharmacol. 2016;7:424. doi: 10.3389/fphar.2016.00424. PubMed DOI PMC

Stark M.S., Gray E.S., Isaacs T., Chen F.K., Millward M., McEvoy A., Zaenker P., Ziman M., Soyer H.P., Glasson W.J., et al. A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision. Transl. Vis. Sci. Technol. 2019;8:12. doi: 10.1167/tvst.8.6.12. PubMed DOI PMC

Haritoglou I., Wolf A., Maier T., Haritoglou C., Hein R., Schaller U.C. Osteopontin and ’melanoma inhibitory activity’: Comparison of two serological tumor markers in metastatic uveal melanoma patients. Ophthalmologica. 2009;223:239–243. doi: 10.1159/000206139. PubMed DOI

Barak V., Frenkel S., Kalickman I., Maniotis A.J., Folberg R., Pe’er J. Serum markers to detect metastatic uveal melanoma. Anticancer Res. 2007;27:1897–1900. PubMed PMC

Barisione G., Fabbi M., Gino A., Queirolo P., Orgiano L., Spano L., Picasso V., Pfeffer U., Mosci C., Jager M.J., et al. Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma. JAMA Ophthalmol. 2015;133:1013–1021. doi: 10.1001/jamaophthalmol.2015.1766. PubMed DOI

Velez G., Nguyen H.V., Chemudupati T., Ludwig C.A., Toral M., Reddy S., Mruthyunjaya P., Mahajan V.B. Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk. Mol. Cancer. 2021;20:39. doi: 10.1186/s12943-021-01336-4. PubMed DOI PMC

Reiniger I.W., Schaller U.C., Haritoglou C., Hein R., Bosserhoff A.K., Kampik A., Mueller A.J. “Melanoma inhibitory activity” (MIA): A promising serological tumour marker in metastatic uveal melanoma. Graefes Arch. Clin. Exp. Ophthalmol. 2005;243:1161–1166. doi: 10.1007/s00417-005-1171-4. PubMed DOI

An T., Qin S., Xu Y., Tang Y., Huang Y., Situ B., Inal J.M., Zheng L. Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis. J. Extracell. Vesicles. 2015;4:27522. doi: 10.3402/jev.v4.27522. PubMed DOI PMC

Alegre E., Zubiri L., Perez-Gracia J.L., González-Cao M., Soria L., Martín-Algarra S., González A. Circulating melanoma exosomes as diagnostic and prognosis biomarkers. Clin. Chim. Acta. 2016;454:28–32. doi: 10.1016/j.cca.2015.12.031. PubMed DOI

Szajnik M., Derbis M., Lach M., Patalas P., Michalak M., Drzewiecka H., Szpurek D., Nowakowski A., Spaczynski M., Baranowski W., et al. Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy. Gynecol. Obstet. 2013;3(Suppl.4) doi: 10.4172/2161-0932.S4-003. PubMed DOI PMC

Khan S., Jutzy J.M., Valenzuela M.M., Turay D., Aspe J.R., Ashok A., Mirshahidi S., Mercola D., Lilly M.B., Wall N.R. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS ONE. 2012;7:e46737. doi: 10.1371/journal.pone.0046737. PubMed DOI PMC

Tsering T., Laskaris A., Abdouh M., Bustamante P., Parent S., Jin E., Ferrier S.T., Arena G., Burnier J.V. Uveal Melanoma-Derived Extracellular Vesicles Display Transforming Potential and Carry Protein Cargo Involved in Metastatic Niche Preparation. Cancers. 2020;12:2923. doi: 10.3390/cancers12102923. PubMed DOI PMC

Surman M., Hoja-Łukowicz D., Szwed S., Kędracka-Krok S., Jankowska U., Kurtyka M., Drożdż A., Lityńska A., Stępień E., Przybyło M. An Insight into the Proteome of Uveal Melanoma-Derived Ectosomes Reveals the Presence of Potentially Useful Biomarkers. Int. J. Mol. Sci. 2019;20:3789. doi: 10.3390/ijms20153789. PubMed DOI PMC

Théry C., Witwer K.W., Aikawa E., Alcaraz M.J., Anderson J.D., Andriantsitohaina R., Antoniou A., Arab T., Archer F., Atkin-Smith G.K., et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles. 2018;7:1535750. doi: 10.1080/20013078.2018.1535750. PubMed DOI PMC

Kulcenty K., Piotrowski I., Wroblewska J.P., Wasiewicz J., Suchorska A.W.M. The Composition of Surgical Wound Fluids from Breast Cancer Patients is Affected by Intraoperative Radiotherapy Treatment and Depends on the Molecular Subtype of Breast Cancer. Cancers. 2019;12:11. doi: 10.3390/cancers12010011. PubMed DOI PMC

Zhao Y., Weber S.R., Lease J., Russo M., Siedlecki C.A., Xu L.C., Chen H., Wang W., Ford M., Simó R., et al. Liquid Biopsy of Vitreous Reveals an Abundant Vesicle Population Consistent With the Size and Morphology of Exosomes. Transl. Vis. Sci. Technol. 2018;7:6. doi: 10.1167/tvst.7.3.6. PubMed DOI PMC

Ragusa M., Barbagallo C., Statello L., Caltabiano R., Russo A., Puzzo L., Avitabile T., Longo A., Toro M.D., Barbagallo D., et al. MiRNA profiling in vitreous humor, vitreal exosomes and serum from uveal melanoma patients: Pathological and diagnostic implications. Cancer Biol. Ther. 2015;16:1387–1396. doi: 10.1080/15384047.2015.1046021. PubMed DOI PMC

Eldh M., Olofsson Bagge R., Lässer C., Svanvik J., Sjöstrand M., Mattsson J., Lindnér P., Choi D.S., Gho Y.S., Lötvall J. MicroRNA in exosomes isolated directly from the liver circulation in patients with metastatic uveal melanoma. BMC Cancer. 2014;14:962. doi: 10.1186/1471-2407-14-962. PubMed DOI PMC

Angi M., Kalirai H., Prendergast S., Simpson D., Hammond D.E., Madigan M.C., Beynon R.J., Coupland S.E. In-depth proteomic profiling of the uveal melanoma secretome. Oncotarget. 2016;7:49623–49635. doi: 10.18632/oncotarget.10418. PubMed DOI PMC

Piotrowski I., Kulcenty K., Suchorska W. Interplay between inflammation and cancer. Rep. Pract. Oncol. Radiother. 2020;25:422–427. doi: 10.1016/j.rpor.2020.04.004. PubMed DOI PMC

Greten F.R., Grivennikov S.I. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51:27–41. doi: 10.1016/j.immuni.2019.06.025. PubMed DOI PMC

Brocker C., Thompson D., Matsumoto A., Nebert D.W., Vasiliou V. Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum. Genom. 2010;5:30–55. doi: 10.1186/1479-7364-5-1-30. PubMed DOI PMC

Setrerrahmane S., Xu H. Tumor-related interleukins: Old validated targets for new anti-cancer drug development. Mol. Cancer. 2017;16:153. doi: 10.1186/s12943-017-0721-9. PubMed DOI PMC

Lee C.S., Jun I.H., Kim T.I., Byeon S.H., Koh H.J., Lee S.C. Expression of 12 cytokines in aqueous humour of uveal melanoma before and after combined Ruthenium-106 brachytherapy and transpupillary thermotherapy. Acta Ophthalmol. 2012;90:e314–e320. doi: 10.1111/j.1755-3768.2012.02392.x. PubMed DOI

Dunavoelgyi R., Funk M., Sacu S., Georgopoulos M., Zlabinger G., Zehetmayer M., Schmidt-Erfurth U. Intraocular activation of angiogenic and inflammatory pathways in uveal melanoma. Retina. 2012;32:1373–1384. doi: 10.1097/IAE.0b013e318239e299. PubMed DOI

Nagarkatti-Gude N., Bronkhorst I.H., van Duinen S.G., Luyten G.P., Jager M.J. Cytokines and chemokines in the vitreous fluid of eyes with uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2012;53:6748–6755. doi: 10.1167/iovs.12-10123. PubMed DOI

Masaoutis C., Kokkali S., Theocharis S. Immunotherapy in uveal melanoma: Novel strategies and opportunities for personalized treatment. Expert Opin. Investig. Drugs. 2021;30:555–569. doi: 10.1080/13543784.2021.1898587. PubMed DOI

Nishina T., Deguchi Y., Ohshima D., Takeda W., Ohtsuka M., Shichino S., Ueha S., Yamazaki S., Kawauchi M., Nakamura E., et al. Interleukin-11-expressing fibroblasts have a unique gene signature correlated with poor prognosis of colorectal cancer. Nat. Commun. 2021;12:2281. doi: 10.1038/s41467-021-22450-3. PubMed DOI PMC

Tao L., Huang G., Wang R., Pan Y., He Z., Chu X., Song H., Chen L. Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway. Sci. Rep. 2016;6:38408. doi: 10.1038/srep38408. PubMed DOI PMC

Johnstone C.N., Chand A., Putoczki T.L., Ernst M. Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer. Cytokine Growth Factor Rev. 2015;26:489–498. doi: 10.1016/j.cytogfr.2015.07.015. PubMed DOI

Putoczki T.L., Ernst M. IL-11 signaling as a therapeutic target for cancer. Immunotherapy. 2015;7:441–453. doi: 10.2217/imt.15.17. PubMed DOI

Fang S., Wang Y., Chun Y.S., Liu H., Ross M.I., Gershenwald J.E., Cormier J.N., Royal R.E., Lucci A., Schacherer C.W., et al. The relationship between blood IL-12p40 level and melanoma progression. Int. J. Cancer. 2015;136:1874–1880. doi: 10.1002/ijc.29182. PubMed DOI PMC

Cooper A.M., Khader S.A. IL-12p40: An inherently agonistic cytokine. Trends Immunol. 2007;28:33–38. doi: 10.1016/j.it.2006.11.002. PubMed DOI

Tugues S., Burkhard S.H., Ohs I., Vrohlings M., Nussbaum K., Vom Berg J., Kulig P., Becher B. New insights into IL-12-mediated tumor suppression. Cell Death Differ. 2015;22:237–246. doi: 10.1038/cdd.2014.134. PubMed DOI PMC

Bisevac J.P., Stanojevic I., Mijuskovic Z., Banovic T., Djukic M., Vojvodic D. High Interleukin 27 Production is Associated with Early Clinical Stage and Localized Disease in Patients with Melanoma. J. Med. Biochem. 2016;35:443–450. doi: 10.1515/jomb-2016-0018. PubMed DOI PMC

Yoshimoto T., Morishima N., Mizoguchi I., Shimizu M., Nagai H., Oniki S., Oka M., Nishigori C., Mizuguchi J. Antiproliferative activity of IL-27 on melanoma. J. Immunol. 2008;180:6527–6535. doi: 10.4049/jimmunol.180.10.6527. PubMed DOI

Fabbi M., Carbotti G., Ferrini S. Dual Roles of IL-27 in Cancer Biology and Immunotherapy. Mediat. Inflamm. 2017;2017:3958069. doi: 10.1155/2017/3958069. PubMed DOI PMC

Lane A.M., Egan K.M., Harmon D., Holbrook A., Munzenrider J.E., Gragoudas E.S. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology. 2009;116:2206–2212. doi: 10.1016/j.ophtha.2009.04.044. PubMed DOI

Nathan F.E., Berd D., Sato T., Shield J.A., Shields C.L., De Potter P., Mastrangelo M.J. BOLD+interferon in the treatment of metastatic uveal melanoma: First report of active systemic therapy. J. Exp. Clin. Cancer Res. 1997;16:201–208. PubMed

Qin Y., Bollin K., de Macedo M.P., Carapeto F., Kim K.B., Roszik J., Wani K.M., Reuben A., Reddy S.T., Williams M.D., et al. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. J. Immunother. Cancer. 2020;8:e000960. doi: 10.1136/jitc-2020-000960. PubMed DOI PMC

Song J., Merbs S.L., Sokoll L.J., Chan D.W., Zhang Z. A multiplex immunoassay of serum biomarkers for the detection of uveal melanoma. Clin. Proteomics. 2019;16:10. doi: 10.1186/s12014-019-9230-8. PubMed DOI PMC

Damento G.M., Pulido J.S., Abbott B.A., Hodge D.O., Dalvin L.A. TNF-Alpha Inhibition and Other Immunosuppressants in the Development of Uveal and Cutaneous Melanoma. Mayo Clin. Proc. 2019;94:1287–1295. doi: 10.1016/j.mayocp.2018.11.033. PubMed DOI

Montfort A., Colacios C., Levade T., Andrieu-Abadie N., Meyer N., Ségui B. The TNF Paradox in Cancer Progression and Immunotherapy. Front. Immunol. 2019;10:1818. doi: 10.3389/fimmu.2019.01818. PubMed DOI PMC

Lejeune F.J., Liénard D., Matter M., Rüegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 2006;6:6. PubMed

Cai X., Cao C., Li J., Chen F., Zhang S., Liu B., Zhang W., Zhang X., Ye L. Inflammatory factor TNF-α promotes the growth of breast cancer via the positive feedback loop of TNFR1/NF-κB (and/or p38)/p-STAT3/HBXIP/TNFR1. Oncotarget. 2017;8:58338–58352. doi: 10.18632/oncotarget.16873. PubMed DOI PMC

Rossi S., Cordella M., Tabolacci C., Nassa G., D’Arcangelo D., Senatore C., Pagnotto P., Magliozzi R., Salvati A., Weisz A., et al. TNF-alpha and metalloproteases as key players in melanoma cells aggressiveness. J. Exp. Clin. Cancer Res. 2018;37:326. doi: 10.1186/s13046-018-0982-1. PubMed DOI PMC

Liu W., Lu X., Shi P., Yang G., Zhou Z., Li W., Mao X., Jiang D., Chen C. TNF-α increases breast cancer stem-like cells through up-regulating TAZ expression via the non-canonical NF-κB pathway. Sci. Rep. 2020;10:1804. doi: 10.1038/s41598-020-58642-y. PubMed DOI PMC

Damento G., Kavoussi S.C., Materin M.A., Salomão D.R., Quiram P.A., Balasubramaniam S., Pulido J.S. Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors. Mayo Clin. Proc. 2014;89:1481–1486. doi: 10.1016/j.mayocp.2014.08.012. PubMed DOI

Taha E.A., Sogawa C., Okusha Y., Kawai H., Oo M.W., Elseoudi A., Lu Y., Nagatsuka H., Kubota S., Satoh A., et al. Knockout of MMP3 Weakens Solid Tumor Organoids and Cancer Extracellular Vesicles. Cancers. 2020;12:1260. doi: 10.3390/cancers12051260. PubMed DOI PMC

Giacomini A., Ghedini G.C., Presta M., Ronca R. Long pentraxin 3: A novel multifaceted player in cancer. Biochim. Biophys. Acta Rev. Cancer. 2018;1869:53–63. doi: 10.1016/j.bbcan.2017.11.004. PubMed DOI

Rathore M., Girard C., Ohanna M., Tichet M., Ben Jouira R., Garcia E., Larbret F., Gesson M., Audebert S., Lacour J.P., et al. Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway. Oncogene. 2019;38:5873–5889. doi: 10.1038/s41388-019-0848-9. PubMed DOI

Coppola D., Szabo M., Boulware D., Muraca P., Alsarraj M., Chambers A.F., Yeatman T.J. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin. Cancer Res. 2004;10:184–190. doi: 10.1158/1078-0432.CCR-1405-2. PubMed DOI

El-Tanani M.K., Yuen H.F., Shi Z., Platt-Higgins A., Buckley N.E., Mullan P.B., Harkin D.P., Johnston P.G., Rudland P.S. Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells. Cancer Sci. 2010;101:1354–1360. doi: 10.1111/j.1349-7006.2010.01561.x. PubMed DOI PMC

Pass H.I., Lott D., Lonardo F., Harbut M., Liu Z., Tang N., Carbone M., Webb C., Wali A. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N. Engl. J. Med. 2005;353:1564–1573. doi: 10.1056/NEJMoa051185. PubMed DOI

Kadkol S.S., Lin A.Y., Barak V., Kalickman I., Leach L., Valyi-Nagy K., Majumdar D., Setty S., Maniotis A.J., Folberg R., et al. Osteopontin expression and serum levels in metastatic uveal melanoma: A pilot study. Investig. Ophthalmol. Vis. Sci. 2006;47:802–806. doi: 10.1167/iovs.05-0422. PubMed DOI PMC

Song J., Zhang Z., Chan D.W. Detection of Uveal Melanoma by Multiplex Immunoassays of Serum Biomarkers. Methods Mol. Biol. 2021;2265:447–459. doi: 10.1186/s12014-019-9230-8. PubMed DOI

Wróblewska J.P., Lach M.S., Ustaszewski A., Kulcenty K., Ibbs M., Jagiełło I., Suchorska W.M., Marszałek A. The Potential Role of Selected miRNA in Uveal Melanoma Primary Tumors as Early Biomarkers of Disease Progression. Genes. 2020;11:271. doi: 10.3390/genes11030271. PubMed DOI PMC

Fitzgerald W., Freeman M.L., Lederman M.M., Vasilieva E., Romero R., Margolis L. A System of Cytokines Encapsulated in ExtraCellular Vesicles. Sci. Rep. 2018;8:8973. doi: 10.1038/s41598-018-27190-x. PubMed DOI PMC

Takov K., Yellon D.M., Davidson S.M. Comparison of small extracellular vesicles isolated from plasma by ultracentrifugation or size-exclusion chromatography: Yield, purity and functional potential. J. Extracell. Vesicles. 2019;8:1560809. doi: 10.1080/20013078.2018.1560809. PubMed DOI PMC